Hydrogen-rich water alleviates cyclosporine A-induced nephrotoxicity via the Keap1/Nrf2 signaling pathway

Yi Lu1,2,3,4, Chun-Fang Li5, Na-Na Ping6

  • 1Key Laboratory of Shannxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Insights

Hydrogen-rich water (HRW) protects against cyclosporine A (CsA)-induced kidney damage by reducing oxidative stress. HRW activates the Keap1/Nrf2 pathway, improving renal function and mitigating CsA nephrotoxicity.

Area of Science:

  • Nephrology
  • Biochemistry
  • Pharmacology

Background:

  • Long-term cyclosporine A (CsA) administration causes chronic nephrotoxicity, characterized by tubular atrophy, apoptosis, and fibrosis, impacting organ transplantation outcomes.
  • Oxidative stress is a key mechanism in CsA-induced kidney damage, but the protective effects of hydrogen-rich water (HRW) and its underlying mechanisms are not fully understood.

Purpose of the Study:

  • To investigate the protective effects of HRW against CsA-induced nephrotoxicity in a rat model.
  • To elucidate the potential mechanisms, particularly the involvement of the Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.

Main Methods:

  • Rats were administered CsA (25 mg/kg/day) and treated with or without HRW (12 mL/kg) for 4 weeks.
  • Evaluated renal function (urinary protein, serum creatinine, blood urea nitrogen), vascular activity, and performed histological analysis (Masson's trichrome, TUNEL staining).
  • Measured oxidative stress markers (ROS, MDA, GSH, SOD) and assessed the Keap1/Nrf2 pathway activation (Keap1, Nrf2, NQO1, HO-1 expression).

Main Results:

  • CsA administration increased oxidative stress (elevated ROS, MDA; reduced GSH, SOD), leading to renal dysfunction, vascular impairment, tubular atrophy, apoptosis, and interstitial fibrosis.
  • HRW treatment significantly reduced oxidative stress markers and improved renal and vascular function.
  • HRW administration decreased Keap1 levels and increased the expression of Nrf2, NADPH dehydrogenase quinone 1 (NQO1), and heme oxygenase 1 (HO-1), indicating Keap1/Nrf2 pathway activation.

Conclusions:

  • HRW effectively restores redox balance and mitigates CsA-induced oxidative stress and kidney damage.
  • HRW protects against CsA nephrotoxicity by activating the Keap1/Nrf2 signaling pathway, offering a potential therapeutic strategy for preventing transplant-related kidney injury.

Related Concept Videos

Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
743
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
121
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
217
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
832